Common Contracts
9 similar Pledge Agreement contracts by Nektar Therapeutics, Oscient Pharmaceuticals Corp, Global Crossing LTD, others
PLEDGE AGREEMENTPledge Agreement • June 1st, 2006 • Global Crossing LTD • Telephone communications (no radiotelephone) • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of May 30, 2006 by and among Global Crossing Limited, an exempt company with limited liability under the laws of Bermuda (the “Grantor”), having its principal executive offices at Wessex House, 45 Reid Street, Hamilton HM12, Bermuda and Wells Fargo Bank, N.A., having an office at Sixth St and Marquette, Ave, MAC N9303-120, Minneapolis, Minnesota 55479, attention Corporate Trust Services (the “Account Office”), (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Indenture.
PLEDGE AGREEMENTPledge Agreement • August 9th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • New York
PLEDGE AGREEMENT, dated as of May 10, 2004 (this “Agreement”), by and among Oscient Pharmaceuticals Corporation, a corporation duly organized and existing under the laws of the Commonwealth of Massachusetts (the “Grantor”), having its principal office at 100 Beaver Street, Waltham, MA 02453, and U.S. Bank National Association (“U.S. Bank”), a national banking association, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Securities (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office at One Federal Street, 3rd Floor, Boston, Massachusetts 02110 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Indenture.
PLEDGE AGREEMENTPledge Agreement • August 9th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • New York
PLEDGE AGREEMENT, dated as of May 10, 2004 (this “Agreement”), by and among Oscient Pharmaceuticals Corporation, a corporation duly organized and existing under the laws of the Commonwealth of Massachusetts (the “Grantor”), having its principal office at 100 Beaver Street, Waltham, MA 02453, and U.S. Bank National Association (“U.S. Bank”), a national banking association, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Securities (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office at One Federal Street, 3rd Floor, Boston, Massachusetts 02110 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Indenture.
PLEDGE AGREEMENTPledge Agreement • May 11th, 2004 • Sunterra Corp • Real estate dealers (for their own account) • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of March 29, 2004 by and among SUNTERRA CORPORATION, a Maryland corporation (the “Grantor”), having its principal executive offices at 3865 West Cheyenne Avenue, North Las Vegas, Nevada 89032 and WELLS FARGO BANK, NATIONAL ASSOCIATION (“Wells Fargo”), having an office at MAC N9303-120, Sixth Street and Marquette Avenue, Minneapolis, MN 55479, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office in Minneapolis c/o: Wells Fargo Bank, N.A., MAC N9303-120, Sixth Street and Marquette Avenue, Minneapolis, MN 55479 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall have
PLEDGE AGREEMENTPledge Agreement • February 2nd, 2004 • Medarex Inc • Services-commercial physical & biological research • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of January 30, 2004 by and among Medarex, Inc., a New Jersey corporation (the “Grantor”), having its principal executive offices at 707 State Road #206, Princeton, New Jersey 08540 and Wilmington Trust Company, having an office at 1100 North Market Street, Wilmington, Delaware 19890, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) through the office of its affiliate in New York c/o: Wilmington Trust, FSB, 520 Madison Avenue, 33rd Floor, New York, New York 10022 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Indenture.
PLEDGE AGREEMENTPledge Agreement • November 3rd, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of October 9, 2003 by and among NEKTAR THERAPEUTICS, a Delaware corporation (the “Grantor”), having its principal executive offices at 150 Industrial Road, San Carlos, California 94070 and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION (“J.P. Morgan”), having an office at 560 Mission Street, 13th Floor, San Francisco, California 94105, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office in New York c/o: J.P. Morgan Chase Bank, Institutional Trust Services, 4 New York Plaza, 15th Floor, New York, New York 10004 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall
PLEDGE AGREEMENTPledge Agreement • October 20th, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of October 9, 2003 by and among NEKTAR THERAPEUTICS, a Delaware corporation (the “Grantor”), having its principal executive offices at 150 Industrial Road, San Carlos, California 94070 and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION (“J.P. Morgan”), having an office at 560 Mission Street, 13th Floor, San Francisco, California 94105, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office in New York c/o: J.P. Morgan Chase Bank, Institutional Trust Services, 4 New York Plaza, 15th Floor, New York, New York 10004 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall
PLEDGE AGREEMENTPledge Agreement • October 10th, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of October 9, 2003 by and among NEKTAR THERAPEUTICS, a Delaware corporation (the “Grantor”), having its principal executive offices at 150 Industrial Road, San Carlos, California 94070 and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION (“J.P. Morgan”), having an office at 560 Mission Street, 13th Floor, San Francisco, California 94105, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office in New York c/o: J.P. Morgan Chase Bank, Institutional Trust Services, 4 New York Plaza, 15th Floor, New York, New York 10004 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall
PLEDGE AGREEMENTPledge Agreement • July 2nd, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of June 30, 2003 by and among NEKTAR THERAPEUTICS, a Delaware corporation (the “Grantor”), having its principal executive offices at 150 Industrial Road, San Carlos, California 94070 and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION (“J.P. Morgan”), having an office at 560 Mission Street, 13th Floor, San Francisco, California 94105, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office in New York c/o: J.P. Morgan Chase Bank, Institutional Trust Services, 4 New York Plaza, 15th Floor, New York, New York 10004 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall ha
